Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018

Stock Information for Moleculin Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Moleculin Biotech Inc.

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.